SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Biotechnology

Healthcare
$29.68 +2.49%

+$0.45 today

Market cap
$993.14M
Beta
-0.34
P/E (TTM)
-14.1
EPS (TTM)
-$1.32
52W Low $17.06High $32.44

Volume 0.10M

Average 0.09M

SGP Total Non-current Liabilities

All obligations due after more than one year.

SpyGlass Pharma, Inc. Common StockNASDAQ: SGP

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities of $1.61M in Q1 FY2026

Q1 FY2026 total non-current liabilities was $1.61M.

Context

  • Total non-current liabilities amounted to 0.6% of total assets at the end of Q1 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.61M-99.2% QoQ
Last fiscal yearDec 2025
$206.12M— YoY
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
206.12M USD
Year-over-year change
—

Total Non-current Liabilities vs competitors

How SGP compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Total non-current liabilities amounts to 0.6% of total assets for SGP, versus a peer median of 14.1%.
SGP Competitors
Total Non-current Liabilities for SGP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ALCAlcon Inc.Sep 2026$6.84B USD+6.2%-1.4%21.8%
BLCOBausch + Lomb CorporationJun 2026$5.53B USD+0.7%+26.7%39.9%
GKOSGlaukos CorporationJun 2026$135.71M USD-4.9%-33.9%14.7%
OCULOcular Therapeutix, Inc.Mar 2026$103.27M USD+1.2%+7.7%14.1%
STAASTAAR Surgical CompanyApr 2026$37.76M USD-3.3%+16.4%8.4%
SGHTSight Sciences, Inc.Mar 2026$37.64M USD-5.7%+4.7%34.3%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$20.28M USD-9.8%-25.0%7.0%
RXSTRxSight, Inc.Mar 2026$9.32M USD-15.2%-38.8%3.1%
OCSOculis Holding AGMar 2026CHF 3.47M CHF+65.9%-70.5%1.4%
SGPSpyGlass Pharma, Inc. Common StockMar 2026$1.61M USD——0.6%
Peer median (excluding SGP) —-3.3%-1.4%14.1%

Competitors are the stored peer set for SGP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

SpyGlass Pharma, Inc. Common Stock

NASDAQ:SGP

Intrinsic Alpha fair value

Locked

Current Price

$29.68

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.